ORIC Q2 2024 Earnings — ORIC Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ORICORIC Pharmaceuticals, Inc.

$1B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$36M

Net Income

-$32M

EPS (Diluted)

$-0.45

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$329M

Total Liabilities

$27M

Stockholders' Equity

$302M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$36M	-$25M	-44.1%
Net Income	-$32M	-$23M	-39.3%